Lista de obras -

"In situ" vaccination for systemic effects in follicular lymphoma

artículo científico publicado en 2015

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

artículo científico publicado en 2016

A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma

artículo científico publicado en 2016

Allogeneic stem-cell transplantation in adults 1985-2012: results and development

artículo científico publicado en 2014

Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients

artículo científico publicado en 2012

Biodistribution and dosimetry results from a phase 1 trial of (177)Lu-lilotomab satetraxetan antibody-radionuclide conjugate therapy

artículo científico publicado en 2017

Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae

artículo científico publicado en 2002

Clonal hematopoiesis evolves from pre-treatment clones and stabilizes after end of chemotherapy in patients with MCL

artículo científico publicado en 2020

Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma

artículo científico publicado en 2014

Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway

artículo científico publicado en 2015

Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myeloma.

artículo científico publicado en 2015

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

scientific article published on 21 December 2020

Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling

artículo científico publicado en 2016

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma

artículo científico publicado en 2020

Hepatitis B virus-infected peripheral blood progenitor cell harvests in liquid nitrogen freezer containing non-infectious products

artículo científico publicado en 2004

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.

artículo científico publicado en 2013

High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study

artículo científico publicado en 2011

High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era

artículo científico publicado en 2014

High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial

artículo científico publicado en 2013

High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008.

artículo científico publicado en 2013

High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment

artículo científico publicado en 2013

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

artículo científico publicado en 2018

Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk

artículo científico publicado en 2020

Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases

artículo científico publicado en 2011

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

scientific article published on 19 September 2019

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of mutations in mantle cell lymphoma

artículo científico publicado en 2018

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.

artículo científico publicado en 2016

Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma

Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years

artículo científico publicado en 2017

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

artículo científico publicado en 2008

Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?

artículo científico publicado en 2009

Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations

artículo científico publicado en 2016

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

artículo científico publicado en 2016

Molecular cytogenetic characterization of t(14;19)(q32;p13), a new recurrent translocation in B cell malignancies

artículo científico publicado en 2007

Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma

scientific article published on 18 November 2013

Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis.

artículo científico publicado en 2016

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

artículo científico publicado en 2012

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

artículo científico publicado en 2014

Persistent changes in the immune system 4-10 years after ABMT.

artículo científico publicado en 1999

Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

scientific article published on 01 September 2020

Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma

artículo científico publicado en 2012

Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen.

artículo científico publicado en 2007

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

artículo científico publicado en 2009

Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma

article

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

artículo científico publicado en 2003

Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years

artículo científico publicado en 2015

Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate

artículo científico publicado en 2016

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

artículo científico publicado en 2011

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study

artículo científico publicado en 2014

Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma

artículo científico publicado en 2014

Should alternative therapists treat cancer--what is the opinion of oncology health personnel?

artículo científico publicado el 6 de noviembre de 2003

T cells expressing checkpoint receptor TIGIT are enriched in follicular lymphoma tumors and characterized by reversible suppression of T-cell receptor signaling

artículo científico publicado en 2017

T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells

artículo científico publicado en 2011

TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma

scientific article published on 18 January 2019

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

artículo científico publicado en 2017

Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA

artículo científico publicado en 2016

The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy

scientific article published on 06 August 2018

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

artículo científico publicado en 2009

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion

artículo científico publicado en 2009

Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan

artículo científico publicado en 2016

Use of Alternative Medicine Among Norwegian Cancer Patients is Associated with Mental Distress - A Follow-up Study.

artículo científico publicado en 2002

[Alternative medicine--attitudes and use among physicians, nurses and administrative staff employed in hospitals in northern Norway]

scientific article published on 01 March 2003

[Can the immune system target cancer?]

scientific article published on 01 April 2012

[Mental distress and use of alternative medicine among cancer patients]

scientific article published on 01 March 2003

[Should complementary therapies be offered in hospitals?]

artículo científico publicado en 2004

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

artículo científico publicado en 2015

p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma

artículo científico publicado en 2020

Lista de obras de

"In situ" vaccination for systemic effects in follicular lymphoma

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma

Allogeneic stem-cell transplantation in adults 1985-2012: results and development

Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients

Biodistribution and dosimetry results from a phase 1 trial of (177)Lu-lilotomab satetraxetan antibody-radionuclide conjugate therapy

Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae

Clonal hematopoiesis evolves from pre-treatment clones and stabilizes after end of chemotherapy in patients with MCL

Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma

Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway

Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myeloma.

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma

Hepatitis B virus-infected peripheral blood progenitor cell harvests in liquid nitrogen freezer containing non-infectious products

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.

High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study

High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era

High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial

High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008.

High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk

Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of mutations in mantle cell lymphoma

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.

Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma

Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?

Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

Molecular cytogenetic characterization of t(14;19)(q32;p13), a new recurrent translocation in B cell malignancies

Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma

Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis.

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Persistent changes in the immune system 4-10 years after ABMT.

Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma

Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen.

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years

Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study

Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma

Should alternative therapists treat cancer--what is the opinion of oncology health personnel?

T cells expressing checkpoint receptor TIGIT are enriched in follicular lymphoma tumors and characterized by reversible suppression of T-cell receptor signaling

T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells

TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA

The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion

Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan

Use of Alternative Medicine Among Norwegian Cancer Patients is Associated with Mental Distress - A Follow-up Study.

[Alternative medicine--attitudes and use among physicians, nurses and administrative staff employed in hospitals in northern Norway]

[Can the immune system target cancer?]

[Mental distress and use of alternative medicine among cancer patients]

[Should complementary therapies be offered in hospitals?]

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma